No Data
No Data
Immuneering to Present at the Jefferies Global Healthcare Conference
PDF Version CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF m
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage...
Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)
Immuneering Reports Q1 Results
Express News | Immuneering Corp : Jefferies Cuts Target Price to $1.5 From $3
No Data